Bangkok, Thailand — 2025
Villa Medical Center Phuket (www.thailandstemcell.com), a leading biotech platform for regenerative and cell-based therapies in Southeast Asia, has officially partnered with Genepeutics (www.gnptbio.com) to supply GMP-grade human serum to researchers, clinicians, and biomanufacturing facilities across Thailand. This initiative strengthens Thailand’s growing infrastructure in stem cell therapy and Advanced Therapy Medicinal Product (ATMP) development by offering safer, xeno-free, and compliant alternatives to fetal bovine serum (FBS).
As a regional subsidiary of Atlantis Bioscience Singapore (www.atlantisbioscience.com), Villa Medical Center Phuket plays a pivotal role in introducing high-quality biologics and regenerative tools to key healthcare and research markets in Asia. With this 2025 partnership, Atlantis bridges the gap between globally certified serum sourcing and local demand for clinical-grade components in Thailand’s rapidly evolving cell therapy sector.
Human Serum: A Game-Changer in Stem Cell Therapy and ATMP Manufacturing
Human serum is increasingly recognized as a superior alternative to animal-derived serum in cell therapy and regenerative research. Unlike FBS, which introduces cross-species variability and ethical concerns, GMP-compliant human serum is collected from healthy screened human donors under tightly controlled conditions. This ensures:
- Biological compatibility with human cells
- Minimized immunogenic risk
- Reduced regulatory barriers for clinical use
- Compliance with GMP, ISO, and regulatory authority standards
For mesenchymal stem cell (MSC) expansion, hematopoietic stem cell support, and immune cell activation, human serum enables higher reproducibility and safer transitions from bench to bedside. As Thailand positions itself for increased ATMP clinical trials and biotech growth, reliable access to such reagents is mission critical.
Why Genepeutics? Global Standards, Clinical Readiness
Genepeutics (www.gnptbio.com), based in the United States, is a renowned biomanufacturer of GMP-grade human blood-derived products. Their serum is processed in FDA-inspected, ISO 13485-certified facilities and undergoes rigorous screening, filtration, and viral inactivation procedures to meet international guidelines.
Key features of Genepeutics’ GMP Human Serum include:
- Donor screening for HIV, HBV, HCV, HTLV, Syphilis
- Sterile filtration at 0.2 μm and triple verification
- Traceable batch documentation and Certificate of Analysis (CoA)
- Xeno-free, additive-free, and ready for ATMP and stem cell use
This serum is already used globally in cell therapy programs, including MSC clinical trials, CAR-T production, NK cell expansion, and exosome manufacturing. With Villa Medical Center Phuket as an authorized distributor in Thailand, local laboratories now have immediate access to one of the industry’s most trusted serum sources.
Local Delivery with Global Assurance
Through its centralized cold-chain distribution platform in Thailand, Villa Medical Center Phuket ensures that Genepeutics’ GMP human serum is delivered with:
- Validated cold-chain logistics
- On-time scheduling for time-sensitive R&D and clinical timelines
- Regulatory documentation support for Thai FDA submission
- Bilingual (English-Thai) technical assistance and product guidance
Clients include stem cell research labs, university hospitals, exosome product developers, and ATMP trial sponsors throughout Bangkok, Chiang Mai, and medical innovation corridors in Eastern Economic Zones.
Villa Medical Center Phuket also offers serum lot reservation, small-batch trial orders, and custom volume packaging to meet the specific needs of Thai institutions working in high-precision research environments.
Driving Thailand’s Leadership in Cell and Gene Therapy
Thailand is increasingly recognized for its investments in cell and gene therapy, with growing clinical applications in:
- Osteoarthritis and orthopaedic regenerative care
- Immunomodulation for autoimmune and neurodegenerative diseases
- Personalized cancer therapies involving NK and T-cell-based products
- Exosome-based skin and anti-aging formulations
However, sourcing GMP-compatible reagents including human-derived serum has historically been a bottleneck. The collaboration between Atlantis and Genepeutics directly addresses this challenge.
By offering human serum as a GMP-grade input, Atlantis supports the full spectrum of ATMP development, from early-phase R&D to clinical-grade cell expansion, product formulation, and long-term storage.
Backed by Atlantis Bioscience Singapore
The 2025 rollout in Thailand is powered by the operational and regulatory ecosystem of Atlantis Bioscience Singapore, a regional leader in:
- GMP media and serum alternatives
- Contract manufacturing for biologics
- Custom reagents for stem cell, immune, and probiotic platforms
- Exosome kit development and therapeutic formulation
Atlantis Bioscience ensures that all Genepeutics’ products distributed by Villa Medical Center Phuket are compliant with:
- WHO and PIC/S standards for cell therapy input materials
- ASEAN harmonization regulations for ATMP classification
- Local Thai FDA import licensing and CoA requirements
This ensures that researchers and clinicians in Thailand receive not only the best materials but also the full technical, legal, and scientific support necessary for regulated stem cell therapy development.
Education and Technical Training for Serum Applications
Recognizing the need for education in serum alternatives, Villa Medical Center Phuket is rolling out a 2025 training series for Thai labs and hospitals that will cover:
- Best practices in transitioning from FBS to human serum
- GMP documentation and batch record integration
- MSC proliferation and differentiation using human serum
- NK and T cell protocols adapted for human-compatible growth
Workshops, webinars, and in-lab demos will help research teams validate protocols, troubleshoot performance issues, and align with clinical GMP guidelines.
This knowledge-sharing initiative is central to Atlantis’ mission of empowering the Thai biotech sector through scientific capability building.
Aligning with Thailand’s Biomedical Strategy
The Thai government has identified biomedical innovation as a key pillar of national growth. The availability of human serum supports the expansion of:
- Biobank and stem cell repositories
- Regulated cell therapy trials under Thai FDA
- Hospital-based ATMP pilot programs
- Exportable biologics produced under local GMP conditions
Villa Medical Center Phuket’ distribution of Genepeutics’ human serum aligns with these objectives, offering foundational infrastructure for medical institutions and R&D hubs seeking to commercialize their discoveries ethically and efficiently.
Conclusion: Advancing ATMP Infrastructure, One Reagent at a Time
The 2025 launch of GMP human serum supply in Thailand, made possible through the partnership between Villa Medical Center Phuket and Genepeutics, represents a vital leap forward in Thailand’s preparedness for stem cell and ATMP innovation. With global-grade biologics now available locally, Thai institutions are equipped to elevate the quality, safety, and reproducibility of their cellular therapies.
This initiative underscores Villa Medical Center Phuket’ ongoing role in building Southeast Asia’s biomedical foundation—one trusted reagent, partnership, and training program at a time.
Villa Medical Center Phuket
Villa Sukhothai, Soi Pasak 8, Choeng Thale,
Thalang District, Phuket, Thailand
Email: atlantisphuket@gmail.com
Phone/WhatsApp: +66 99 301 6969